Quick Takeaways
- Soleus Capital Master Fund, L.P. filed SCHEDULE 13G for UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share (URGN).
- Disclosed ownership: 5%.
- Date of event: 13 Jun 2025.
Quoteable Key Fact
"Soleus Capital Master Fund, L.P. disclosed 5% ownership in UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share (URGN) on 13 Jun 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member | |
| Soleus Capital, LLC | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member | |
| Soleus Capital Group, LLC | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member | |
| Soleus Capital Management, L.P. | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member | |
| Soleus GP, LLC | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member | |
| Guy Levy | 5% | 2,325,000 | 0 | 2,325,000 | /s/ Guy Levy | Guy Levy/Managing Member |